4. Hrvatski kongres kliniËke citologije 4th Croatian Congress ... - Penta

Recommendations

Info

4. Hrvatski kongres kliniËke citologije / 1. Hrvatski simpozij analitiËke citologije / 2. Hrvatski simpozij citotehnologije 52 Klinička citologija - Plenarna i pozvana predavanja PARVOVIRUS B 19 INDUCED PURE RED CELL APLASIA IN IMMUNOCOMPROMISED PATIENT AFTER LIVER TRANSPLANTATION Mrzljak A1 , Kardum Skelin I1 , Čolić Cvrlje V1 , Filipec Kanižaj T1 , Šušterčić D1 , Guštin D2 , Kocman B3 1 Department of Medicine, University Hospital Merkur, Zagreb, Croatia, 2Department of Anesthesiology and Intensive Care, University Hospital Merkur, Zagreb, Croatia, 3 Department of Surgery, University Hospital, Merkur, Zagreb, Croatia Reported here is a case of human parvovirus B19 (PVB19) induced pure red-cell aplasia (PRCA) in immunocompromised patient after orthotopic liver transplantation (OLT). PVB19 is a small, single-stranded DNA whose target cell is the erythroid progenitor in bone marrow. Manifestations of PVB19 infection vary with the immunologic status of the patient, ranging from asymptomatic to severe infections and PRCA. Post-transplant PRCA is induced either by immunosuppression or PVB19. In the presented case, bone marrow aspiration characterized by the absence of mature erythroid precursors and detection of PVB19 DNA in blood led to treatment with high-dose intravenous human immunoglobulins (IVIG) and subsequent recovery of erythropoiesis. Due to insufficient antibody response in transplanted patients, suppression of the PVB19 infection is delayed and repetitive treatments may be administrated in attempt of reversing PRCA. anna.mrzljak@gmail.com
Clinical Cytology - Plenary and Invited Lectures COLLECTION AND COMPOSITION OF AUTOLOGOUS PERIPHERAL BLOOD STEM CELLS GRAFT IN PATIENTS WITH ACUTE MYELOID LEUKEMIA: INFLUENCE ON HE- MATOPOIETIC RECOVERY AND OUTCOME Raos M1 , Nemet D2 , Bojanić I1 , Sertić D2 , Batinić D3 , Dušak V4 , Mazić S1 , Dubravčić K3 , Serventi-Seiwerth R2 , Mrsić M2 , Golubić-Ćepulić B1 , Labar B2 1Department of Transfusion Medicine and Cellular Therapy, Clinical Hospital Center Zagreb, Zagreb, Croatia 2Division of Hematology, Department of Internal Medicine, Clinical Hospital Center Zagreb, Zagreb, Croatia 3Division of Immunology, Department of Laboratory Diagnostics, Clinical Hospital Center Zagreb, Zagreb, Croatia 4 Department for Quantitative Methods, University of Zagreb, Faculty of Organisation and Informatics, Varaždin, Croatia Hematopoietic stem cell (HSC) transplantation is a standard approach in the treatment of hematological malignant diseases. For the last 15 years the main source of cells for trasplantation have been peripheral blood stem cells (PBSC). With the availability of hematopoietic growth factors and understanding the advantages of treatment with PBSC, the application of bone marrow (BM) was supplanted. The aim of this survey was to explore the success of PBSC collection, the factors which influence the success of PBSC collection, the composition and the quality of graft and their infuence on hematopoietic recovery and outcome after transplantation in patients with acute myeloid leukemia (AML). PBSC were collected by the method of leukapheresis after applying a combination of chemotherapy and growth factors or only growth factors. The quality of graft was determined with the clonogenic progenitor cell assay and with the flow citometry analysis. Of the total 134 patients with AML, who were sumitted to HSC mobilization, the collection was successful in 78 (58.2%) patients. The collection was more successful after the first than after the second attempt of HSC mobilization (49% vs 11%). The criteria for effective mobilization were the number of leukocytes >3 x 109/L and the concentration of CD34+ cells >20 x 103/mL in the peripheral blood on the first day of leukapheresis. The number of CD34+ cells infused had the strongest impact on hematopoietic recovery. We noted significantly faster hematological recovery of neutrophils and platelets, fewer number of transfused units of red blood cells and platelets, shorter duration of the tranfusion support, shorter treatment with intravenous antibiotic therapy and shorter hospitalization after PBSC compared to BM transplantation. These advantages could provide their standard application in the treatment of patients with AML. mraos@kbc-zagreb.hr 53 4 th Croatian Congress of Clinical Cytology / 1 st Croatian Symposium of Analytical Cytology / 2 nd Croatian Symposium of Cytotechnology
Page 1:
4. Hrvatski kongres kliniËke citol
Page 4 and 5: 4. Hrvatski kongres kliniËke citol
Page 13 and 14: Final programme and abstract book
Page 15: UTORAK, 13.10.2009. SRIJEDA, 14.10.
Page 104 and 105:
Page 106 and 107:
Page 108 and 109:
Page 110 and 111:
Page 112 and 113:
Page 114 and 115:
Page 116 and 117:
Page 118 and 119:
Page 120 and 121:
Page 122 and 123:
Page 124 and 125:
Page 126 and 127:
Page 128 and 129:
Page 130 and 131:
Page 132 and 133:
Page 134 and 135:
Page 136 and 137:
Page 138 and 139:
Page 140 and 141:
Page 142 and 143:
Page 144 and 145:
Page 146 and 147:
Page 148 and 149:
Page 150 and 151:
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
Page 158 and 159:
Page 160 and 161:
Page 162 and 163:
Page 164 and 165:
Page 166 and 167:
Page 168 and 169:
Page 170 and 171:
Page 172 and 173:
Page 174 and 175:
Page 176 and 177:
Page 178 and 179:
Page 180 and 181:
Page 182 and 183:
Page 184 and 185:
Page 186 and 187:
Page 188 and 189:
Page 190 and 191:
Page 192 and 193:
Page 194:
show all

4. Hrvatski kongres kliniËke citologije 4th Croatian Congress ... - Penta

Create successful ePaper yourself

Delete template?

Save as template?